FDA's Expanded Decision Tree: What Food Manufacturers Should Know about FDA's New Toxicity Screening Tool

By David Graham

Food chemical regulation is drawing heightened attention from consumers, advocacy groups, state legislatures, Congress, and FDA. Some of that attention is political, some scientific, and some reflects broader consumer concern about ultra-processed foods, artificial colors, food packaging chemicals, Generally Recognized as Safe (GRAS) determinations, and whether FDA can keep pace with changes in the food supply.

For food manufacturers, the practical point is more straightforward: FDA is building new tools to evaluate chemicals in food and food-contact materials more systematically. One of the most important is the Expanded Decision Tree (EDT), FDA’s new structure-based toxicity screening tool. FDA has now released materials explaining how the Expanded Decision Tree works and how it may be used in premarket and post-market food chemical review.

FDA’s Expanded Decision Tree has a defined screening role. It gives FDA and industry a structured way to screen chemical structures for chronic oral toxicity concerns and flag issues that may require additional review. A complete safety analysis still must address actual exposure and the legal basis for any food or food-contact use.

What Is FDA’s Expanded Decision Tree for Food Chemical Safety?

FDA describes the EDT as a New Approach Method that uses chemical structure, metabolism, and toxicity information to classify chemicals by estimated chronic oral toxic potential. It is a modernized and expanded version of the original Cramer Decision Tree, which has long been used to provide a preliminary estimate of toxic potential when chemical-specific testing data are limited.

The EDT uses a series of structure-based yes-or-no questions to sort chemicals into six classes of toxic potential. Each class is associated with a Threshold of Toxicological Concern (TTC), expressed in micrograms per kilogram of body weight per day. FDA’s materials explain that a substance classified in a particular EDT class is not expected to pose a safety concern if exposure does not exceed that class TTC.

That detail matters because FDA describes current use as manual and requiring organic chemistry and metabolism expertise. FDA is working toward automation, which could allow chemicals to be classified more quickly and consistently. For now, applying the EDT remains a technical exercise.

What FDA’s EDT Means for Food Ingredients and Food Contact Substances

Companies still need to follow applicable FDA pathways, including FDA approval, food additive petitions, food contact notifications, GRAS substantiation, and exposure evaluation. FDA is explicit that the EDT is one tool that may be used in assessing the safety of a substance used in food or in contact with food. Statutory review and approval processes continue to govern when they apply.

The EDT has a defined applicability domain. FDA says it was designed to predict chronic oral toxicity for structurally defined organic compounds. Its applicability domain does not include toxic elements such as lead, mercury, cadmium, or arsenic; non-hydrolyzable polymers such as low-density polyethylene; large peptides such as insulin; nanomaterials; or proteins. FDA also states that the EDT has been evaluated only for oral exposure, not other routes of exposure.

Manufacturers should avoid assuming that a low EDT classification ends the analysis. FDA states that EDT predictions should be considered together with real-world exposure and other information, including Absorption, Distribution, Metabolism and Excretion (ADME), toxicology, epidemiology, and other relevant data. FDA further cautions that even a chemical in the lowest estimated toxicity category could be unsafe if used above its class TTC.

Why FDA’s Expanded Decision Tree Matters for Post-Market Food Chemical Review

The EDT is being released after FDA finalized a more systematic post-market process for chemicals in food on May 12, 2026. FDA’s post-market food chemical safety framework includes signal identification and triage, prioritization, scientific assessment, and risk management. FDA says chemicals under review will be posted publicly for transparency.

The EDT fits into that broader system. FDA says the tool may help support premarket assessment, identify data gaps, prioritize chemicals for post-market evaluation, and inform cumulative toxicity and mixture assessments once fully operational and automated.

EDT classifications may become relevant before FDA formally requires anything new. In the context of FDA submissions, FDA says EDT classifications may help determine what information is needed to evaluate a new food contact material or food additive submission. FDA also notes that companies developing a new ingredient or making a GRAS conclusion might run a substance or impurity through the EDT to identify potential safety concerns and targeted testing needs.

For packaging and food-contact companies, this is particularly important. FDA’s EDT materials expressly refer to substances that may come into contact with food, and packaging-law commentators have already noted that industry members may benefit from reviewing how proprietary chemical portfolios align with the EDT’s toxicity classifications.

How FDA’s EDT Fits into GRAS Reform and Food Chemical Transparency

GRAS reform remains a separate legal and policy question. The EDT leaves existing GRAS notification and public-disclosure rules unchanged. Gardner Law recently discussed growing congressional interest in GRAS reform, including proposals that could reshape how ingredient safety is demonstrated and documented. FDA’s 2026 Human Foods Program deliverables also identify a proposed regulation that would require submission of GRAS notices for all new substances claimed to be GRAS.

The EDT adds a scientific layer to that same practical issue. If FDA has a tool that can flag structural toxicity concerns or data gaps, companies should expect more questions about chemical identity, intended use, exposure, impurities, and the basis for safety conclusions. This is especially true for ingredients, processing aids, food-contact substances, contaminants, and impurities supported by older files.

The same point applies outside GRAS. As Gardner Law has noted in the labeling context, FDA’s current views and enforcement posture do not eliminate broader litigation or state-law risk. Companies must evaluate regulatory developments alongside class action exposure, state authorities, competitor challenges, and consumer expectations. The EDT is a scientific tool whose use may affect the defensibility of regulatory positions in more than one forum.

Practical EDT Takeaways for Food Manufacturers, Packaging Companies, and Ingredient Suppliers

Manufacturers should build the EDT into product and portfolio planning now, particularly for substances with known chemical identity and structure.

First, companies should know which substances in their products and supply chains could plausibly fall within the EDT’s scope. That includes intentionally added ingredients, flavor components, processing aids, food-contact substances, migrants, impurities, degradation products, and contaminants where chemical identity and structure are known.

Second, companies should identify safety files that may be vulnerable because they are old, incomplete, difficult to trace, or dependent on assumptions that may no longer reflect current exposure. FDA specifically notes that the EDT may be useful in evaluating substances approved 40 or 50 years ago to determine whether further study is needed.

Third, companies should pay close attention to exposure. The EDT may estimate toxic potential. Safety still depends on use level, dietary exposure, consumer population, and available chemical-specific data. A strong safety file should connect chemical identity, intended technical effect, conditions of use, exposure estimates, impurities, and toxicology support.

Fourth, companies should prepare for FDA’s eventual automation of the EDT. Automation could make the tool more accessible to FDA reviewers, industry, advocacy groups, and possibly the public. That may increase consistency, but it may also make screening results easier to generate and easier to question.

Finally, companies should monitor FDA engagement opportunities. FDA has said it plans to further refine the EDT and engage stakeholders, including through listening sessions with technical, scientific, and trade groups.

What FDA’s Expanded Decision Tree Signals About the Future of Food Chemical Regulation

It is a meaningful signal of where FDA is heading. Food chemical safety review is becoming more structured, more transparent, more data-driven, and more connected to post-market prioritization. Manufacturers that understand the EDT now will be better positioned to answer FDA questions later.

For manufacturers, the practical takeaway is that safety files need to be current, organized, scientifically defensible, and tied to actual exposure. EDT results may increasingly shape the questions FDA asks along the way.

How Gardner Law Can Help

Gardner Law advises food, beverage, ingredient, supplement, packaging, and consumer product companies on FDA compliance, GRAS strategy, food additive and food contact issues, labeling, recalls, enforcement risk, and litigation exposure. Companies evaluating how FDA’s Expanded Decision Tree, post-market food chemical review process, or emerging GRAS reform proposals may affect their products should consider reviewing ingredient portfolios, supplier documentation, safety files, exposure assumptions, and labeling claims before questions arise.

Gardner Law can help companies assess where the EDT may matter, identify documentation gaps, and develop practical strategies for FDA engagement, product review, and risk management.